QPS Holdings, LLC
35
Followers
Personal Information
Organization / Workplace
Newark, Delaware United States
Industry
Medical / Health Care / Pharmaceuticals
Website
www.qps.com
About
QPS is a GCP/GLP-compliant CRO that supports drug discovery as well as preclinical and clinical drug development. We provide quality services to clients worldwide in DMPK, Toxicology, Bioanalysis, Translational Medicine, and Clinical Development. Our regional laboratories are located at our headquarters in Newark, DE, USA; Springfield, MO, USA; Groningen, The Netherlands; Hyderabad, India; and Taipei, Taiwan.
Tags
qps
cro
clinical trials
clinical
bioanalysis
biomarkers
drug
elisa
clinical research
dmpk
toxicology
contract research
lc-ms/ms
translational medicine
drug development
preclinical
trial
pk
assay development
ria
immunogenicity
bioanalytical services
in vivo
qwba
development
pharmacodynamic
neutralizing antibody
multiplexing
genotyping
cell based assays
anti drug antibodies
in vitro
pharmacogenomics
rnai therapeutics
monoclonal antibodies
clinical trial
bioequivalence
adme
tlm
pgx
late phase
gene therapy
transdermal
research
models
biologics
imaging
bioavailability
phase 1
gcp
icp-ms
neuropharmacology
dermal
preclinical research
early phase clinical
oncology
pk studies
assay
early stage clinical
transgenic
biosimilar act
biosimilars
patients
trials
proteins
marg
ind
first-in-man
clinical pharmacology
icp
biosimilar
nab
sad
mad
fim
ddi
lc-icp/ms
large molecule
immunology
immunobioanalysis
pharmaceutical
laboratories
ind program management
glp
discovery
contract research organization
biotech
study data
phase ii-iv
operations
medical devices
late stage
clinical operations
pet-studies
quantitative whole-body autoradiography
late phase clinical
generics
fda
skin
delivery
drug metabolism
respiratory
drug development programs
nce
in vivo studies
neuroscience
program
follow on biologics
filgrastim
be-study
autoradiography
small molecules
large molecules
cns
pediatrics
ich
metabolism
peptides
phenotyping
metabolic profiling
human mass balance
early stage
safety pharmacology
phase i
candidate selection
study
ms
ada
rituximab
ame
protein binding
biotransformation
systemic delivery
sensitization
safety
risk assessment
irritation
cutaneous
adhesion
small molecule
sample analysis
oglionucleotides
monclonal antibodies
dried blood spots
analytical validation
analytical method development
vaccine studies
pharmaceuticals
pharmaceutical product development
microdosing
toxicity
safety tests
reproductive toxicology
histopathology
genetic toxicology
generic toxicology
general toxicology
gene mutation assay
fertility
clinical pathology
chromosome abberration assay
biocompatibility testing
aaalac
rats
non-transgenic
neuronal tissue culture
neurodegenerative diseases
mode of action
mice
ko
generation
drug profiling
animal
immune response
biotherapeutic
pharmacology
smoking trials
respiratory trials
research studies
negative pressure room
infection control
covid-19
contamination
radiotracers
radioactive drugs
drug efficacy
metabolic reaction phenotyping
mass balance
vedotinantibody drug conjugates
toxin
maytansine
linker
dm1
brentuximab
auristatine
antibody
adc
biomolecules
antibody drug conjugates
protein biotherapeutics
gene interference
oligonucleotides
gene therapy approvals
pharmacokinetics
qpcr
genetics
participants
strategies
pediatric trials
somatropin
epoetin alfa
chmp
tau
protein
knock out
bbb
amyloid beta
abeta
pk/pd
sirnas
sirna
rnai
rna
interference
gene-silencing
dsrnas
dsrna
cell-specific
population
pop pk
pk analysis
regulations
nda submission
drug approval
transdermal delivery systems
white paper
topical
tdds
route
patch
ointments
lotions
gels
formulation
foams
diseases
dermatology
creams
clinical trial site
mabs
mass spectrometry
lba
ligand
binding
c14
metabolite identification
metabolite profiling
metabolic pathways
tissue distribution
investigational drug
route and rate of excretion
radiolabel
austria
patient recruitment.
patient studies
lps challenge
spirometry
asthma
allergy
copd
pulmonology
poc-studies
imp
gmp
eu
annex 13
impd
ib
ccmo
ethics committee
clinical trial application
ec
cta
trial submission
early clinical research
the netherlands
advantages
timeline
regulatory
animal models
behavioral
drug candidate
drugs
biologicals
nbe
in vitro studies
batbi
baseline-adjusted transferrinbound iron
baseline-adjusted total iron
bati
be-studies
fe(oh)3
ferric hydroxide
hemoglobin
cytochrome
iron
iron sucrose
accurate
healthy
timely
volunteers
data
first in human
europe
usa
tissue pharmacokinetics
rtpcr
phosphor imaging
quantitative real-time pcr
micro-autoradiography
brain distribution
huntington’s disease
radiolabeled drugs
cyclodextrin
niemann-pick disease
microautoradiography
radioactivity
autoradioluminography
food effect
ba
pd
drug interaction
mra
diabetes
elderly
be
thresholds
third molar extraction model
quantitative sensory testing
qst
m3
neuropathic
heat
investigation
cold
healthy volunteers
ich gcp
pain
mechanical pressure
nociceptive
mri
prodromal
ad
alzheimer's
alzheimer
distribution
absorption
excretion
enzymes
iodinated
125i
compounds
antibodies
biotechnology
reaction
metabolic
radioquantification
plasma protein binding
program management
phase ii
proof of concept
lc-icp-ms
gyros
See more
- Presentations
- Documents
- Infographics